| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000025944 |
| Receipt No. | R000029828 |
| Scientific Title | A verification study of influence on defecation by consumption of the polydextrose-containing food for adult male and female with constipation tendency |
| Date of disclosure of the study information | 2017/02/05 |
| Last modified on | 2020/10/05 (Ver. 3) |
| Basic information | ||
| Public title | A verification study of influence on defecation by consumption of the polydextrose-containing food for adult male and female with constipation tendency | |
| Acronym | Verification of influence on defecation by consumption of the polydextrose-containing food | |
| Scientific Title | A verification study of influence on defecation by consumption of the polydextrose-containing food for adult male and female with constipation tendency | |
| Scientific Title:Acronym | Verification of influence on defecation by consumption of the polydextrose-containing food | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Confirm the effect on defecation by ingesting the polydextrose containing food for males and females with subjective symptoms of constipation tendency. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Number of defecation (days of defecation) |
| Key secondary outcomes | *Feces property (amount, shape, color, smell, sensation after defecation)
*Intestinal microflora *Physicochemical analysis of feces ( fecal organic acid, fecal decay products) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake 2 packs of test food in a day at any time for 2 weeks. Keep interval minimum 6 hrs between test foods intake. | |
| Interventions/Control_2 | Intake 2 packs of control food in a day at any time for 2 weeks. Keep interval minimum 6 hrs between control foods intake. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1)Males and females aged 20 to 59 years old.
(2) Subjects who defecate 2 to 4 times in a week. (3) Subjects who show understanding of the study procedures and agreement with participating the study by written informed consent prior to the study. |
|||
| Key exclusion criteria | (1)Subjects who are diagnosed as a strong constipation by a doctor.
(2)Subjects who are diagnosed with diabetes (including boundary type) by a doctor. (3)Subjects who regularly use medical drugs and/or supplements that have bowel movement improving effect. (4)Pregnant or expected pregnant women, or lactating women. (5)Subjects who have previous and/or current medical history of serious disease in heart, liver, kidney and/or digestive trucks. (6)Subjects who excessive alcohol intake. (7)Subjects who have extremely irregular life rhythm, and subjects who have midnight work or irregular shift work. (8)Subjects who have previous medical history of drug and/or food allergy. (9)Subjects who are participating the other clinical tests of medicines or foods. Subjects who participated other clinical tests of medicines or foods within 4-weeks prior to the current study. Subjects who are planning to participate in other clinical tests of medicines or foods after agreeing with participating in this study. (10)Subjects who donated over 200mL blood and/or blood components within the last one month to the current study. (11)Males who donated over 400mL blood within the last three month to the current study. (12) Females who donated over 400mL blood within the last four month to the current study. (13) Males who will be collected over 1200mL blood, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. (14) Females who will be collected over 800mL blood, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. (15)Others who have been determined ineligible by principal investigator or sub-investigator. |
|||
| Target sample size | 90 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Clinical Research Planning Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN | ||||||
| TEL | 03-5297-3112 | ||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Sales & Planning Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN | ||||||
| TEL | 03-5297-3112 | ||||||
| Homepage URL | |||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Sponsor | |
| Institute | CPCC Company Limited |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Otsuka Pharmaceutical Factory, Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Institutional Review Board of Chiyoda Paramedical Care Clinic |
| Address | 2F Chushin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan |
| Tel | 03-5297-5548 |
| IRB@cpcc.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029828 |